



Progestin-Only and Combined Oral Contraceptives and Receptor-
Defined Premenopausal Breast Cancer Risk: the Norwegian Women 
and Cancer Study 
Marit Busund1, Nora S. Bugge1, Tonje Braaten1, Marit Waaseth2, Charlotta Rylander1, Eiliv Lund1 
1Department of Community Medicine, UiT The Arctic University of Norway 
2Department of Pharmacy, UiT The Arctic University of Norway 
Corresponding author: Marit Katinka Busund, Department of Community Medicine, Faculty of 
Health Sciences, UiT The Arctic University of Norway, 9037 Tromsø, Norway; e-mail: 
marit.busund@uit.no. * 
Keywords: Breast cancer subtypes; Oral contraceptives; Tumor heterogeneity; Prospective cohort 
study; Multiple imputation 
Abbreviations: BMI = Body mass index; CI = Confidence interval; COC = Combined oral 
contraceptive; ER = Estrogen receptor; HR = Hazard ratio; NOWAC = The Norwegian Women and 
Cancer Study; OC = Oral contraceptive; POC = Progestin-only contraceptive; PR = Progesterone 
receptor.  
Article category: Cancer epidemiology 
What’s new: Use of combined oral contraceptives (COC) is associated with increased risk of breast 
cancer and, predominantly, its hormone receptor-negative subtypes. The association between 
progestin-only contraceptives (POC) and receptor-defined subtypes of breast cancer is unknown. This 
prospective, population-based cohort is the first study to assess the effect of POC use on breast cancer 
subtypes. Here, the authors find associations between POC use for five years or more and hormone 
receptor-positive subtypes. 
                                                          
* Disclaimer: Some of the data in this article are from the Cancer Registry of Norway. The Cancer 





Receptor-defined subtypes of breast cancer represent distinct cancer types and have differences in risk 
factors. Whether the two main hormonal forms of oral contraceptives (OCs); i.e. progestin-only (POC) 
and combined oral contraceptives (COC), are differentially associated with these subtypes are not well 
known. The aim of this study was to assess the effect of POC and COC use on hormone receptor-
defined breast cancer risk in premenopausal women in a prospective population-based cohort – The 
Norwegian Women and Cancer study (NOWAC). Information on OC use was collected from 74,862 
premenopausal women at baseline. Updated information was applied when follow-up information 
became available. Multiple imputation was performed to handle missing data, and multivariable Cox 
regression models were used to calculate hazard ratios (HR) for breast cancer. 1245 incident invasive 
breast cancer cases occurred. POC use ≥ five years was associated with ER+ (HR = 1.59, 95% CI 1.09 
– 2.32, ptrend = 0.03) and ER+/PR+ cancer (HR = 1.63, 95% CI 1.07 – 2.48, ptrend = 0.05), and was not 
associated with ER- (pheterogeneity = 0.36) or ER-/PR- (pheterogeneity = 0.49) cancer. COC use was associated 
with ER- and ER-/PR- cancer, but did not increase risk of ER+ and ER+/PR+ cancer. Current COC 
use gave different estimates for ER/PR-defined subtypes (pheterogeneity = 0.04). This is the first study to 
show significant associations between POC use and hormone receptor-positive breast cancer. The lack 
of power to distinguish effects of POC use on subtype development calls for the need of larger studies 





Breast cancer is the most common cancer in women, and the leading cause of cancer death among 
females worldwide 1. Reproductive factors such as early menarche, late menopause, nulliparity and 
high age at first birth are known risk factors for breast cancer 2-4. The role of these reproductive factors 
in breast cancer etiology points towards an essential contributive effect of endogenous female sex 
hormones in the carcinogenesis of breast tissue. Exogenous female hormones are also associated with 
breast cancer. In addition to hormone therapy (HT), estrogen-progestin contraceptives (combined oral 
contraceptives; COCs), are classified as carcinogenic to humans with regards to cervical, breast and 
liver cancer by the International Agency for Research on Cancer 5.  
The association between oral contraceptives (OCs) and breast cancer has been extensively 
studied for decades. In 1996, a comprehensive pooled analysis of 54 epidemiologic studies found a 
slightly increased risk of breast cancer associated with current and recent use of COC, and a cessation 
of risk after 10 years since last use 6. This has later been confirmed by other studies 7-10. Some reports 
suggest a stronger association between OC use and breast cancer in younger women compared to older 
women 11-13, reflecting the increase in risk associated with recent OC use. Due to a small proportion of 
women using OCs less than 10 years before onset of menopause in the NOWAC cohort (< 10%), and 
to the overwhelming evidence of a time-dependent relationship as a function of time since last OC use 
6, 10, 14, i.e. no effect after 10 years since last use, the current article concerns premenopausal women 
only.  
Receptor-defined subtypes of breast cancer represent distinct entities of disease and have 
differences in risk factors 15-17. These subtypes are defined based on the expression of the hormone 
receptors estrogen receptor (ER) and progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2). Prior studies are inconsistent regarding associations between OC use and risk of 
receptor-defined subtypes of breast cancer. Some propose that OC use is associated with increased risk 
of hormone receptor-negative breast cancer 18-22, whereas others suggest a decreased risk of hormone 




has been reported 25 as well as no association with either subtype 26-29, or similar associations across 
subtypes 19, 30.  
The pooled analysis found no effect of progestin-only contraceptive (POC) use and breast 
cancer overall 31. Previous studies on POC and breast cancer are scarce. To date, no study has 
addressed associations between POC use and subtypes of breast cancer. Norwegian data is suitable for 
studying POC use due to a substantial amount of users. Thus, the aim of this study was to assess the 
effect of POC and COC on hormone receptor-defined breast cancer risk in a representative sample of 
premenopausal Norwegian women.  
Materials and methods 
Study population 
The Norwegian Women and Cancer study (NOWAC) is a prospective national population-based 
cohort of 172,000 Norwegian women. Initiated in 1991, women aged 30-70 were randomly selected 
by the Central Population Registry and invited to participate. Out of 327,476 invited women in total 
during the period 1991 to 2007, 172,478 returned a completed questionnaire, providing an overall 
participation rate of approximately 53%. Statistics Norway substituted identification numbers with 
serial numbers on the questionnaires. Questionnaire data on lifestyle and health were collected up to 
three times at four to six year intervals to provide updated information on exposures. NOWAC has 
acceptable external validity 32 and has been described in detail elsewhere 33.  
 For the analyses presented here, 88,258 women who were postmenopausal or 53 years of age 
or older at baseline were excluded 34. Additional exclusion criteria: HT-users at baseline (n = 6,786), 
prevalent cancers at baseline other than non-melanoma skin cancer (ICD-10 C44) (n = 1,018), women 
who emigrated or died before baseline (n = 16), women who were 10 years or younger at first birth (n 
= 2) and women with missing OC, POC or COC status at baseline (n = 1,540). This left a total of 
74,862 women for the current analyses. Follow-up information from a second questionnaire was 




Assessment of OC exposure 
Information on exposure to OCs was obtained by self-administered questionnaires. General questions 
on OC use were asked, such as ever use, age at first use, duration of use and current use. Furthermore, 
the women were asked to denote specific periods with OC use, which was defined as any continuous 
use of one specified OC brand for at least 1 month. To facilitate recall, the questionnaires contained a 
photo booklet with pictures and names of the different OC brands available on the Norwegian market 
up to the time of mailing. Up to date, no more than 42 different OC brands have been sold in Norway. 
We stratified OC use into POC use and COC use based on OC brands used. The internal validity with 
regard to OC use assessment in NOWAC has been found to be satisfying 33. 
Repeated measurements 
Updated information on OC exposure was obtained from follow-up questionnaires. Women who 
reported ever use at baseline and had missing status or reported never use at follow-up were 
categorized as ever users at follow-up. We applied baseline information on OC exposure until follow-
up information became available. Women were censored from the study at the time they reached 
menopause, started using HT, were diagnosed with incident cancer (except non-melanoma skin 
cancer), died or emigrated, whichever occurred first. All participants were followed-up until 31. 
December 2015. 
Identification of breast cancer cases, death and emigration 
The Norwegian 11-digit national identification number, which includes information on date of birth 
and sex 35, allowed linkage of the participants to different national registers. Follow-up information on 
incident breast cancer was collected annually by linkage to the Cancer Registry of Norway, which is 
estimated to be virtually complete due to compulsory reporting from all pathological laboratories, 
hospitals and general practitioners in the country 36. Year of diagnosis ranged from 1991 to 2015. The 
classification of breast cancer (ICD-10 C50) was performed according to the 10th revision of the 
International Statistical Classification of Diseases, Injuries and Causes of Death. Information on death 
and emigration was obtained through linkage to the Cause of Death Registry and the Central 




Breast cancer subtypes 
ER, PR and HER2 status is ascertained by immunohistochemical and in situ hybridization techniques 
conducted at pathological departments across the country and submitted to the Cancer Registry. ER 
negative status was defined as <10% reactivity until January 2012, and <1% reactivity from February 
2012 and onwards due to change in treatment protocols for breast cancer patients in Norway. PR 
negativity was defined as <10% reactivity. Contemporary epidemiological studies include HER2 in 
the breast cancer subtype definition. However, due to large amounts of missing values for this 
variable, we focused on subtypes based on hormone receptor status only. The subgroups used in the 
current article (i.e. ER+, ER-, ER+/PR+ and ER-/PR-) are not mutually exclusive and do not add up to 
the total amount of cases. 
Statistical analysis 
Repeated measurements of OC, POC and COC use were applied in the analysis of total, ER-defined 
and ER/PR-defined premenopausal breast cancer. Hazard ratios (HRs) with 95% confidence intervals 
(CIs) were estimated using Cox proportional hazards models with attained age as the time scale. 
Separate regression models were constructed for subtype outcomes, allowing women who experienced 
another subtype than the one defined as failure to be censored at the time when this subtype occurred 
37. 
 Premenopausal breast cancer was defined as incident breast cancer diagnosed prior to or 
during the same year as the woman’s menopause. Age at menopause was set to the given age at which 
the woman’s menstruation stopped. If age at menopause was missing at baseline, we used reported age 
at menopause from follow-up questionnaires. Women with unknown menopausal status or irregular 
menses were considered postmenopausal at age 53 or older. This cut-off was based on the definition 
used in the Million Women Study34, and later in the NOWAC study 38.  
 The multivariable analyses included established or potential risk factors as covariates, which 
were obtained from the questionnaires. If a linear trend was observed for any covariate, this covariate 
was treated as continuous. Covariates that changed the regression coefficient with less than 10% were 




following covariates: BMI (continuous), history of breast cancer in mother (yes, no), age at menarche 
(continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, ≥ 10 g/day), and a combined variable including 
parity (0, 1, 2, ≥ 3 children) and age at first birth (age < 25, 25-29, ≥ 30). For the analysis addressing 
COC exposure, the model was adjusted for POC use (ever, never), and vice versa.  
The HRs of breast cancer subtypes were tested for heterogeneity by the Wald test. For 
duration variables, heterogeneity between linear trends were tested. All p-values were two-sided. The 
proportional hazards assumption was evaluated by tests of Schoenfeld residuals and by graphical 
inspection of a log-log survival plot. All analyses were performed using the statistical package 
STATA, version 14.  
Multiple imputation 
Under the assumption that data was missing at random 39, multiple imputation was used to handle 
missing information. In order to reduce sampling variability from the imputation simulations, the 
missing values were replaced by imputed values from twenty duplicate datasets 39. The imputation 
model included all covariates used in the multivariable analyses, age at baseline and follow-up, and the 
Nelson-Aalen cumulative hazard estimator as predictors.  
Two types of missing values occurred due to both item and wave non-response. First, values 
were missing due to missing information in the questionnaires (item non-response). These included 
missing covariates at baseline (e.g. alcohol consumption [n = 1,651], age at menarche [n = 1,192] and 
BMI [n = 1,477]), missing duration of OC use at baseline (n = 1,180) or follow-up (n = 23,850), and 
time since last use at baseline (n = 1,293) or follow-up (n = 23,634). Second, missing values at follow-
up were due to non-response of a second questionnaire (wave non-response, n = 23,012). These 
comprised OC status, POC status and duration, and COC status and duration. In order to avoid 
possible inconsistencies in status of use at the two points in time, we imputed possible changes in 
status of OC use and used this information to assign the status at follow-up as current, former, or never 
use. Similarly, we computed OC duration at follow-up from the imputation of additional use since 
baseline in order to avoid lower imputed values at follow-up compared to baseline 40. The estimates 




corresponding 95% CIs 41. Sensitivity analysis was conducted to ensure that risk estimates were 
similar in complete case analysis and multiple imputation analysis.  
Ethics 
NOWAC has been approved by the Regional Committees for Medical and Health Research Ethics 
(REC) and the Norwegian Data Inspectorate. The participants received written information about the 
study and future linkages to national registers, along with invitation to receive a second questionnaire. 
Return of a completed questionnaire was considered consent to participate. A second questionnaire 
was only sent to participants who had agreed to receive one. 
Results 
A total of 1,245 incident premenopausal breast cancer cases occurred during 580017 person-years of 
follow-up. Mean follow-up time was 7.8 years. Among the 1,245 cancer cases, there were 679 ER+ 
cases, 191 ER- cases, 375 cases with missing ER status, 578 PR+ cases, 281 PR- cases and 386 cases 
with missing PR status. When combining the hormone receptor statuses, they comprised 540 
ER+/PR+ cases, 130 ER+/PR- cases, 38 ER-/PR+ cases, 151 ER-/PR- cases and 386 cases with 
missing hormone receptor status.  
Distribution of characteristics at baseline among the study population and premenopausal 
breast cancer cases is presented in Table 1. In addition to a larger proportion with familial breast 
cancer, women who developed premenopausal breast cancer tended to be younger, have lower BMI, 
lower parity and higher age at first birth compared to the whole cohort.  
Current OC use, more than 10 years duration of OC use and less than 10 years since last use 
were associated with premenopausal breast cancer as well as all receptor defined subtypes (Table 2), 
except for current OC use not being associated with ER+/PR+ cancer. More than 20 years since last 
use was also associated with ER-/PR- cancer. In addition, ever and former use of OCs was associated 
with ER- and ER-/PR- breast cancer.  
 The main findings of this study are presented in Tables 3 and 4, displaying stratified analysis 




1.09 – 2.32) and ER+/PR+ (HR = 1.63, 95% CI 1.07 – 2.48) cancer. In women who were POC users 
and never COC users, the corresponding increase in risk was 1.87 (95% CI 1.21 – 2.91) for ER+ 
cancer (Table 4). However, we observed no significant difference in risk estimates between subtypes 
with regard to POC use (pER+vs.ER-=0.36 and pER+/PR+vs.ER-/PR-=0.49). Ever, current, former and ≥ five 
years use of COCs increased the risk of ER- and ER-/PR- disease. The risk of ER-/PR- cancer (HR = 
2.39, 95% CI 1.14 – 5.04) was significantly different from the risk of ER+/PR+ cancer in current COC 
users (pheterogeneity = 0.04).  
Appendix Table 1 displays the distribution of OC, POC and COC use and missing values among the 
study population at baseline and follow-up. 
Results were similar in the complete case analyses. Stratified analyses on POC and COC use without 
using multiple imputation (Appendix Table 2) also indicated positive associations between POC use ≥ 
five years and ER+ cancer (HR = 1.60, 95% CI 1.09 – 2.35) and ER+/PR+ cancer (HR = 1.64, 95% CI 
1.07 – 2.51).  
Discussion 
The main finding of our study was that POC use was associated with hormone receptor-positive 
premenopausal breast cancer if used for five years or more. Thus, our prospective, population-based 
study has unraveled more exact associations between the main hormonal constituents of OCs and 
receptor-defined breast cancer risk in premenopausal women. Dissimilar associations between POC 
and COC use on hormone receptor-defined breast cancer suggests that the exogenous hormones 
estrogen and progestin might have differential roles in subtype carcinogenesis.  
Some of our findings confirm existing knowledge: we have observed that OC use slightly 
increases risk of premenopausal breast cancer. The increase in risk associated with duration of use 
could reflect long-term users being more likely to be current or recent users. Although the total risk 
elevation is modest with regard to ever use (12%), it is noteworthy due to the frequent use of OCs 




Associations between OC use and ER- or ER-/PR- breast cancer is in agreement with previous 
studies 18, 19, 21, 22. Dolle et al. found increased risk of ER negative breast cancer with several aspects of 
OC use (i.e. ever use, duration, age at first use and years since first and last use), while no significant 
associations were found with ER+ breast cancer 18. Beaber et al. found significantly increased risks for 
both ER-positive and ER-negative breast cancer with current use and duration of use 19, as we did in 
our analysis.  
When stratifying by hormonal content, POC and COC use were differently associated with 
hormone receptor-defined subtypes. However, heterogeneity tests for POC use were insignificant and 
unequal associations could be due to a small number of POC users in the hormone receptor-negative 
groups. As limited power is an issue when addressing POC use in relation to hormone receptor-
negative cancer, one cannot rule out the possibility that POC use increases risk of this subtype as well. 
The increased risk of breast cancer provided by POC use is in line with some 9 and in contrast to other 
studies 31, 42. Although used as HT, one study found increased risk of breast cancer associated with 
current use of oral progestins for 4.5 years or more before menopause 43. These studies have not 
assessed POC associations in relation to receptor-defined breast cancer.  
Our findings further imply that general OC use is also associated with hormone receptor-
positive cancers, which is in contrast to most studies 18-22, 29. Since POC use has been more common in 
Scandinavian countries than in the US 44, a higher portion of POCs in our data could influence OC 
associations towards hormone receptor-positivity. Previously mentioned studies defined OC use as 
equivalent to COC use only 19, 25, or they did not specify what type of OCs were encompassed as such 
18, 20, 24. Moreover, Non-Caucasians are scarce in our cohort which explains the relatively smaller 
portion of triple negative cases and consequently hormone receptor-negative cases in our study, as this 
subtype is more common among African-American women 45.  
The biological mechanism linking progestin to breast cancer development is a subject of 
controversy. It is hypothesized that the proliferative effect of progestins on mammary epithelium 




between the ER and the PR enables PR activation to provide estrogen-mediated proliferative response 
47, which also could influence disease development.  
Several challenges arise when studying subtypes of disease. Firstly, the potential of 
misclassification is noteworthy. Pathologists from wide-ranging laboratories conduct hormone 
receptor status assays across the country. There is a certain degree of variety in laboratory techniques, 
scoring methods and interpretation of data. In sum, these represent a subjective influence that opens 
for the possibility of misclassification. Despite that, studies show satisfactory concordance of hormone 
receptor status across laboratories with regard to ER+, ER-, ER+/PR+ and ER-/PR- status 48, as has 
been the main classifications used in the current study. Moreover, a mixture of 1% and 10% cutoff for 
ER negativity could dilute associations, as contemporary clinical knowledge recognizes 1% cutoff as 
true negative ER expression.  
Another major issue involves limited statistical power as we restricted our cohort to 
premenopausal women and only 14% were diagnosed before menopause. Further, there were a 
considerable amount of missing receptor status data as cases were diagnosed as of 1991, at which time 
receptor status testing practices was not standard procedure.  
Missing information at baseline and follow-up was imputed, assuming the information was 
missing at random. This was done in order to keep observations in the analysis and thus improve the 
accuracy of associations. In analyses with smaller subgroups, this method improved the precision of 
the relative risk estimates substantially, without changing their values noteworthy. However, there is a 
possibility that some information was not missing at random, which would result in obtained estimates 
not being completely free from bias. 
To our knowledge, this is the first study to address associations between POC use and 
receptor-defined breast cancer. Strengths of the present study include its prospective design, avoiding 
concerns of selection and recall bias, which is a problem for case-control studies of OCs and breast 
cancer 49. This inevitable concern was the main purpose of creating the prospective NOWAC study. 




the whole country or broader. Further, NOWAC is designed to study impact of hormonal constituents 
on cancer risk by providing reliable and detailed assessment of hormone use. Due to few available OC 
brands on the Norwegian market, this study has reduced potential of exposure misclassification. 
Potential exposure misclassification is likely to be non-differential due to the prospective design of the 
study, and estimates would be biased towards unity. Finally, due to including only premenopausal 
women in our analysis, we get valid results because risk factors and breast cancer characteristics are 
dissimilar in pre- and postmenopausal women 50.  
Despite numerous strengths of the present study, our findings with regard to POC use require 
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Table 1. Baseline characteristics of study population and premenopausal breast cancer cases: The 
NOWAC Study 
  
Study population  
(n = 74,862) 
Premenopausal breast 
cancer cases (n = 1,245) p1 
Age (years) at baseline, no. (%)     < 0.001 
30-34 3,953 (5.3) 104 (8.4)   
35-39 20,853 (27.9) 445 (35.7)   
40-44 19,760 (26.4) 331 (26.6)   
45-49 22,410 (29.9) 297 (23.9)   
> 50 7,886 (10.5) 68 (5.5)   
Mean age (SD) 42.6 (0.0) 41.1 (0.2)   
Body mass index (kg/m2), no. (%)     < 0.001 
< 18.5 2,008 (2.7) 37 (3.0)   
18.5-24.9 52,628 (70.3) 935 (75.1)   
25-29.9 14,717 (19.7) 205 (16.5)   
≥ 30 4,032 (5.4) 46 (3.7)   
Missing 1,477 (2.0) 22 (1.8)   
Mean BMI (SD) 23.4 (0.0) 22.9 (0.1)   
Age (years) at menarche, no. (%)     0.82 
≤ 11 6,624 (8.9) 112 (9.0)   
12 14,822 (19.8) 241 (19.4)   
13 21,505 (28.7) 370 (29.7)   
14 18,136 (24.2) 294 (23.6)   
≥ 15 12,583 (16.8) 196 (15.7)   
Missing 1192 (1.6) 32 (2.6)   
Mean age at menarche (SD) 13.3 (0.0) 13.2 (0.0)   
Parity, no. (%)     < 0.001 
Nulliparous 7,331 (9.8) 151 (12.1)   
1 9,494 (12.7) 184 (14.8)   
2 33,028 (44.1) 557 (44.7)   
≥ 3 25,009 (33.4) 353 (28.4)   
Mean number of children (SD) 2.1 (0.0) 2.0 (0.0)   
Age (years) at first birth, no. (%)      < 0.001 
< 20 9,038 (13.4) 132 (12.1)   
20-24 30,373 (45.0) 429 (39.2)   
25-29 19,820 (29.4) 359 (32.8)   
≥ 30 8,300 (12.3) 174 (15.9)   
Mean age at first birth (SD) 24.2 (0.0) 24.9 (0.1)   
Ever breastfed, no. (%)     0.07 
Yes 51,613 (68.9) 899 (72.2)   
No 3,017 (4.0) 39 (3.1)   
Missing 20,232 (27.0) 307 (24.7)   
Mean duration (months) of breastfeeding (SD) 13.5 (0.1) 13.7 (0.4)   
History of breast cancer in mother, no (%)     < 0.001 
Yes 3,539 (4.7) 109 (8.9)   
Alcohol consumption (g/day), no. (%)     0.08 
None 18,431 (24.6) 285 (22.9)   
0.1-4.9 35,754 (47.8) 609 (48.9)   
5.0-9.9 12,704 (17.0) 209 (16.8)   
≥ 10 6,322 (8.4) 128 (10.3)   
Missing 1,651 (2.2) 14 (1.1)   
Mean alcohol consumption (SD) 3.7 (0.0) 4.0 (0.2)   
Smoking status, no. (%)     0.07 
Never smoker 25,540 (34.1) 395 (31.7)   
Current smoker 24,564 (32.8) 444 (35.7)   
Former smoker 24,720 (33.0) 405 (32.5)   
Missing 38 (0.1) 1 (0.1)   








Table 2. Multivariable adjusted HRs (95% CI) for association between oral contraceptive use and risk of total and hormone receptor-defined premenopausal 
breast cancer: The NOWAC Study  
 All cases 
 ER+ cases  ER- cases  ER+/PR+ cases  ER-/PR- cases 
 
No. (n = 1,245) HR (95% CI)1  No. (n = 679) HR (95% CI)1  No. (n = 191)  HR (95% CI)1  No. (n = 540) HR (95% CI)1  No. (n = 151) HR (95% CI)1 









Never use 379 1.00 (ref.)  216 1.00 (ref.)  49 1.00 (ref.)  167 1.00 (ref.)  37 1.00 (ref.) 
Ever use 866 1.12 (0.99–1.26)  463 1.06 (0.90–1.25)  142 1.48 (1.06–2.06)  373 1.10 (0.91–1.32)  114 1.61 (1.10–2.35) 
Current use 129 1.36 (1.09–1.71)  76 1.36 (1.00–1.85)  27 1.93 (1.10–3.37)  60 1.25 (0.87–1.80)  22 1.98 (1.04–3.76) 
Former use 737 1.09 (0.96–1.24)  387 1.03 (0.87–1.22)  115 1.44 (1.02–2.01)  313 1.08 (0.90–1.31)  92 1.57 (1.07–2.31) 
Duration (years) 
of use     
 
    
 
    
 
    
 
    
1-4 451 1.10 (0.96–1.26) 
 
221 0.97 (0.81–1.18) 
 
70 1.35 (0.93–1.95) 
 
181 1.02 (0.83–1.27) 
 
37 1.50 (0.99–2.28) 
5-9 216 1.02 (0.86–1.21)  125 1.04 (0.82–1.30)  38 1.43 (0.92–2.22)  100 1.06 (0.82–1.37)  58 1.46 (0.88–2.41) 
≥ 10 178 1.29 (1.09–1.54)  103 1.33 (1.05–1.67)  32 1.93 (1.24–2.99)  81 1.34 (1.04–1.74)  28 2.11 (1.29–3.46) 
ptrend2   0.02 
   0.03    0.004    0.04    0.01 
Time (years) since 
last use     
 
    
 
    
 
    
 
    
< 10 371 1.36 (1.15–1.61)  209 1.34 (1.06–1.70)  68 1.71 (1.10–2.66)  170 1.36 (1.04–1.78)  58 1.78 (1.07–2.96) 
11-20 371 1.05 (0.91–1.22)  179 0.94 (0.77–1.15)  60 1.28 (0.86–1.90)  142 0.98 (0.78–1.23)  46 1.44 (0.92–2.25) 
> 20 113 1.04 (0.89–1.23)  66 1.05 (0.85–1.29)  14 1.57 (1.04–2.37)  53 1.10 (0.87–1.38)  10 1.67 (1.05–2.66) 
ptrend2   0.02 
   0.17    0.97    0.30    0.86  
The subgroups (i.e. ER+, ER-, ER+/PR+ and ER-/PR-) are not mutually exclusive and do not add up to the total amount of cases. CI = Confidence interval; ER = Estrogen receptor; HR = Hazard ratio; OC = Oral contraceptives; 
PR = Progesterone receptor. 
1Multivariable analysis adjusted for BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, ≥ 10 g/day), and a combined variable including parity (0, 
1, 2, ≥ 3 children) and age at first birth (age < 25, 25-29, ≥ 30). 





Table 3. Multivariable adjusted HRs (95% CI) for association between combined and progestin-only oral contraceptive use and risk of hormone receptor-
defined premenopausal breast cancer: The NOWAC Study 
 All cases  ER+ cases  ER- cases  ER+/PR+ cases  ER-/PR- cases  
No.  
(n = 1245) 
 
HR (95% CI)1 
 No.  
(n = 679) 
 
HR (95% CI)1 
 No.  
(n = 191) 
 




(n = 540) 
 
HR (95% CI)1 
 No.  
(n = 151) 
 
HR (95% CI)1 
 
p3 
COC use4                
Never OC use 379 1.00 (ref.)  216 1.00 (ref.)  49 1.00 (ref.) 0.07 167 1.00 (ref.)  37 1.00 (ref.)  
Ever COC use 652 1.10 (0.97 - 1.26)  353 1.04 (0.87–1.24)  111 1.50 (1.06–2.13) 0.07 288 1.08 (0.88–1.32)  87 1.60 (1.07–2.38) 0.08 
Current use 77 1.32 (0.99 - 1.77)  43 1.17 (0.77–1.78)  19 2.38 (1.25–4.54) 0.10 33 0.91 (0.53–1.55)  16 2.39 (1.14–5.04) 0.04 
Former use 575 1.09 (0.95 - 1.24)  310 1.03 (0.86–1.23)  92 1.44 (1.01–2.05)  255 1.09 (0.89–1.33)  71 1.54 (1.03–2.31) 0.13 
Duration (years) 
of use  
   
  
 
     
 
   
< 5 346 1.09 (0.94 - 1.27)  180 0.99 (0.81–1.22)  52 1.31 (0.88–1.96)  152 1.06 (0.84–1.33)  42 1.44 (0.92–2.27)  
≥ 5 306 1.11 (0.95 - 1.30)  173 1.09 (0.89–1.34)  59 1.73 (1.17–2.56) 0.36 136 1.10 (0.87–1.39)  45 1.79 (1.14–2.80)  
ptrend
5  0.755   0.35   0.12   0.73   0.28 0.43 
POC use6                
Never OC use 379   216 1.00 (ref.)  49 1.00 (ref.) 0.49 167 1.00 (ref.)  37 1.00 (ref.)  
Ever POC use 171 1.16 (0.95 - 1.42)  97 1.16 (0.89–1.52)  29 1.42 (0.85–2.39) 0.96 79 1.18 (0.87–1.60)  23 1.64 (0.92–2.92) 0.32 
Current use 28 1.42 (0.90 - 2.26)  18 1.52 (0.84–2.77)  6 1.58 (0.48–5.20) 0.47 16 1.75 (0.93–3.28)  5 2.30 (0.69–7.68) 0.69 
Former use 143 1.13 (0.92 - 1.39)  79 1.12 (0.85–1.48)  23 1.41 (0.83–2.40)  63 1.13 (0.82–1.54)  18 1.58 (0.87–2.87) 0.33 
Duration (years) 
of use  
   
  
 
     
 
   
< 5 120 1.06 (0.85 - 1.33)  64 1.01 (0.74–1.37)  23 1.41 (0.80–2.47)  52 1.02 (0.72–1.44)  18 1.59 (0.85–2.99)  
≥ 5 51 1.45 (1.08 - 1.95)  33 1.59 (1.09–2.32)  6 1.46 (0.64–3.31) 0.36 27 1.63 (1.07–2.48)  5 1.79 (0.74–4.36)  
ptrend
5  0.067   0.03   0.97   0.05   0.86 0.49 
CI = Confidence interval; COC = Combined oral contraceptives; ER = Estrogen receptor; HR = Hazard ratio; OC = Oral contraceptives; POC = Progestin-only contraceptives; PR = Progesterone receptor. 
1Multivariable analysis adjusted for BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, ≥ 10 g/day), and a combined variable including parity (0, 1, 2, ≥ 3 children) 
and age at first birth (age < 25, 25-29, ≥ 30).  
2X2 Wald, p heterogeneity between estimate for ER+ and ER- cancer.  
3X2 Wald, p heterogeneity between estimate for ER+/PR+ and ER-/PR- cancer. 
4Analyses on COC use are adjusted for POC use in addition to the above-mentioned covariates. 
5p value, continuous variable. 




Table 4. Multivariable adjusted HRs (95% CI) for association between combined oral contraceptive 
users among never progestin-only users and progestin-only users among never combined oral 
contraceptive users and risk of ER-defined premenopausal breast cancer: The NOWAC Study 
 ER+ cases  ER- cases  
  No. (n = 679) HR (95% CI)
1 No. (n = 191) HR (95% CI)1 p2 
COC use            
Never OC use 216 1.00 (ref.)  49 1.00 (ref.) 
 Ever COC use, never POC use 301 1.03 (0.86–1.23)  95 1.50 (1.06–2.14) 0.06 
Current COC use only  38 1.26 (0.81–1.96)  17 2.64 (1.36–5.14) 0.07 
Former COC use only  263 1.02 (0.85–1.22)  78 1.42 (0.99–2.04) 0.10 
Duration (years) of use       
< 5 yrs 150 0.99 (0.80–1.22)  44 1.31 (0.87–1.98)   
≥ 5 yrs 151 1.08 (0.87–1.33)  51 1.73 (1.16–2.58)   
ptrend3   0.462    0.004  0.03 
POC use            
Never OC use 216 1.00 (ref.)  49 1.00 (ref.)   
Ever POC use, never COC use 45 1.11 (0.80–1.53)  13 1.44 (0.78–2.66)  0.46 
Current POC use only  9 1.50 (0.62–3.64)  3 2.59 (0.63–10.68)  0.52 
Former POC use only  36 1.07 (0.76–1.51)  10 1.33 (0.69–2.57)  0.56 
Duration (years) of use       
< 5 yrs 24 0.79 (0.51–1.22)  10 1.40 (0.68–2.85)   
≥ 5 yrs 21 1.87 (1.21–2.91)  3 1.54 (0.56–4.29)   
ptrend3   0.08    0.18  0.69 
CI = Confidence interval; COC = Combined oral contraceptives; ER = Estrogen receptor; HR = Hazard ratio; OC = Oral 
contraceptives; POC = Progestin-only contraceptives; PR = Progesterone receptor. 
1Multivariable analysis adjusted for BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), 
alcohol consumption (0, 0.1-4.9, 5-9.9, ≥ 10 g/day), and a combined variable including parity (0, 1, 2, ≥ 3 children) and age at first 
birth (age < 25, 25-29, ≥ 30). 
2X2 Wald, p heterogeneity between estimate for ER+ and ER- cancer. 






Appendix Table 1. Distribution of general, combined, and progestin-only oral contraceptive use and 
missing values according to study population at baseline and follow-up – The NOWAC Study 
 
Study population at 
baseline (n = 74,862) 
Study population at 
follow-up (n = 51,850) 
General OC use, no. (%)   
Never use 26,251 (35.1) 18,073 (24.1) 
Ever use 48,611 (64.9) 33,777 (45.1) 
Current use 5,361 (7.2) 1,956 (2.6) 
Former use 43,250 (57.8) 31,821 (42.5) 
Missing 0 (0) 23,012 (30.7) 
Duration (years) of OC use1     
1-4 26,656 (35.6) 18,598 (24.8) 
5-9 12,246 (16.4) 8,490 (11.3) 
≥ 10 8,529 (11.4) 5,851 (7.8) 
Missing 1,180 (1.6) 23,850 (31.9) 
Time (years) since last OC use1   
< 10 16,430 (22.0) 5,569 (7.4) 
11-20 22,077 (29.5) 12,949 (17.3) 
> 20 8,811 (11.8) 14,637 (19.6) 
Missing 1,293 (1.7) 23,634 (31.6) 
COC use, no. (%)     
Never use 38,896 (52.0) 26,738 (35.7) 
Ever use 35,966 (48.0) 25,112 (33.5) 
Current use 3,239 (4.3) 950 (1.3) 
Former use 32,727 (43.7) 24,162 (32.3) 
Missing 0 (0) 23,012 (30.7) 
Duration (years) of COC use1      
< 5 19,765 (26.4) 13,992 (18.7) 
≥ 5 16,201 (21.6) 11,120 (14.9) 
Missing 0 (0) 23,012 (30.7) 
POC use, no. (%)     
Never use 65,771 (87.9) 44,737 (59.8) 
Ever use 9,091 (12.1) 7,113 (9.5) 
Current use 968 (1.3) 379 (0.5) 
Former use 8,123 (10.9) 6,734 (9.0) 
Missing 0 (0) 23,012 (30.7) 
Duration (years) of POC use1     
< 5 6,862 (9.2) 5,423 (7.2) 
≥ 5 2,229 (3.0) 1,690 (2.3) 
Missing 0 (0) 23,012 (30.7) 







Appendix Table 2. Multivariable adjusted HRs (95% CI) for association between COC use and POC use and risk of hormone receptor-defined 
premenopausal breast cancer: The NOWAC Study – complete case analyses 












  Never OC use 203 1.00 (ref.)  45 1.00 (ref.)  157 1.00 (ref.)  34 1.00 (ref.) 
Ever COC use 338 1.00 (0.89–1.14)  108 1.23 (0.98–1.56)  276 1.01 (0.88–1.16)  84 1.33 (1.03–1.72) 
Current use 41 1.12 (0.72–1.73)  19 2.53 (1.32–4.86)  31 0.82 (0.47–1.46)  16 2.52 (1.19–5.34) 
Former use 297 1.03 (0.86–1.24)  89 1.48 (1.02–2.13)  245 1.10 (0.90–1.35)  68 1.56 (1.03–2.37) 
Duration (years) of use                
 
  
< 5 176 1.01 (0.82–1.24)  50 1.33 (0.88–2.01)  149 1.09 (0.86–1.37)  40 1.44 (0.90–2.30) 
≥ 5 162 1.07 (0.87–1.32)  58 1.80 (1.20–2.70)  127 1.08 (0.85–1.38)  44 1.84 (1.16–2.92) 
ptrend3   0.80    0.002    0.43  
 
0.01 
POC use4                
 
  
Never OC use 203 1.00 (ref.)  45 1.00 (ref.)  157 1.00 (ref.)  34 1.00 (ref.) 
Ever POC use 93 0.99 (0.87–1.13)  29 1.17 (0.92–1.49)  76 0.98 (0.85–1.13)  23 1.26 (0.97–1.65) 
Current use 16 1.31 (0.68–2.51)  6 1.68 (0.51–5.55)  14 1.49 (0.75–2.96)  5 2.44 (0.73–8.19) 
Former use 77 1.12 (0.85–1.49)  23 1.48 (0.87–2.54)  62 1.14 (0.83–1.57)  18 1.66 (0.91–3.05) 
Duration (years) of use                
 
  
< 5 61 0.98 (0.71–1.34)  23 1.48 (0.84–2.62)  50 1.01 (0.71–1.43)  18 1.67 (0.88–3.17) 
≥ 5 32 1.60 (1.09–2.35)  6 1.55 (0.68–3.54)  26 1.64 (1.07–2.51)  5 1.91 (0.78–4.67) 
ptrend3 203 0.07 
 
45 0.19  157 0.07  34 0.05 
CI = Confidence interval; COC = Combined oral contraceptives; ER = Estrogen receptor; HR = Hazard ratio; OC = Oral contraceptives; POC = Progestin-only contraceptives; PR = Progesterone 
receptor. 
1Multivariable analysis adjusted for BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, ≥ 10 g/day), and a combined 
variable including parity (0, 1, 2, ≥ 3 children) and age at first birth (age < 25, 25-29, ≥ 30).  
2Analyses on COC use are adjusted for POC use (ever, never) in addition to the above-mentioned covariates. 
3p value, continuous variable. 
4Analyses on POC use are adjusted for COC use (ever, never) in addition to the above-mentioned covariates. 
 
